Get started
Author

Mariem Galuia

Observed name: Mariem GALUIA
ORCID: 0009-0009-1163-8097
Observed ORCID: 0009-0009-1163-8097
OpenAlex ID: A5099019234
Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations
2025 · Mariem Galuia, Julia Fedorova, et al. · Current Oncology · 16
Oncologic outcomes of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: A single-center study.
2025 · Mariem Galuia, Anastasiya Shchatsko, et al. · Journal of Clinical Oncology · 2
PDF
Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) to stratify recurrence risk and adjuvant treatment benefit in a real-world colorectal cancer (CRC) cohort.
2026 · Mariem Galuia, Joseph Gabriel Mchayleh, et al. · Journal of Clinical Oncology · 1
Biosimilars in Gynecologic Cancers: Basic Principles and New Horizons
2025 · Mariem Galuia, Azhar Hussain, et al. · Frontiers in Bioscience-Elite · 1
PDF
The potential of biosimilars in the treatment of colorectal cancer: Focus on bevacizumab
2025 · Mariem Galuia, Ahmed Zakari, et al. · Elsevier eBooks · 1
Circulating tumor DNA (ctDNA) to predict response to neoadjuvant chemotherapy (NAC) and prognosis in patients (pts) with early breast cancer (BC).
2024 · Wassim McHayleh, Ashley Young, et al. · Journal of Clinical Oncology · 1
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
2024 · Ahmad A. Tarhini, Zeynep Eroglu, et al. · Journal of Clinical Oncology · 1
PDF
Response to Zona, E.E.; Israel, J.S. Toward Individualized Management: A Commentary on Perioperative Systemic Therapy Guidelines in Breast Cancer Surgery and Reconstruction. Comment on “Galuia et al. Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations. Curr. Oncol. 2025, 32, 154”
2026 · Mariem Galuia, Julia Fedorova, et al. · Current Oncology
PDF
Idiopathic Thrombocytopenic Purpura (ITP) and Thrombotic Thrombocytopenic Purpura (TTP)
2026 · Mariem Galuia, Mohamed El Khourassani, et al. · Springer eBooks
Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2
2026 · Mariem Galuia, Mark A. Socinski · AME Clinical Trials Review
Any regression of tumor (ART) to discriminate improvement in overall survival (OS) in patients with metastatic urothelial carcinoma (mUC) receiving PD1/L1 inhibitors who exhibit stable disease (SD) by RECIST1.1.
2026 · Bakr Alhayek, Susmita Potti, et al. · Journal of Clinical Oncology
Early peripheral blood neutrophil/lymphocyte ratio (NLR) dynamics to predict primary refractory disease in metastatic urothelial carcinoma (mUC) patients receiving PD1/L1 inhibitors.
2026 · Bakr Alhayek, Susmita Potti, et al. · Journal of Clinical Oncology
Real-world outcomes of hepatic arterial infusion pump therapy.
2026 · Mariem Galuia, Mohamedtaki Abdulaziz Tejani, et al. · Journal of Clinical Oncology
Temporal trends and disparities in pancreatic cancer mortality: A nationwide analysis from 1968-2020.
2025 · Muhammad Ahmad, Malik WZ Khan, et al. · Journal of Clinical Oncology
PDF
Pronounced gender-based and regional disparities in lung cancer mortality in the US: Insights from five decades of nationwide mortality data.
2025 · Muhammad Ahmad, Malik W.Z. Khan, et al. · Journal of Clinical Oncology
L'apport de la bili-IRM dans le diagnostic des pathologies biliaires obstructives
2020 · Mariem GALUIA · Toubkal
Works count: 17
Citation count: 23
H-index: 2
I10-index: 1
Year
Topic
Type